Oral administration 
and usually requires repeated feeding of large (suppression) to massive (anergy/deletion) amounts of autoantigens to be effective. Most importantly, this approach is relatively less effective in animals already systemically sensitized to the fed antigen, such as in animals already harboring autoreactive T cells and, thus, presumably also in humans suffering from an autoimmune disorder. We have previously shown that feeding a single dose of minute amounts of antigens conjugated to cholera toxin B subunit (CTB) can effectively suppress delayed-type hypersensitivity reactions in systemically immune animals. We now report that feeding small amounts of myelin basic protein (MBP) conjugated to CTB either before or after disease induction protected rats from experimental autoimmune encephalomyelitis. Such treatment was as effective in suppressing interleukin 2 production and proliferative responses of lymph node cells to MBP as treatment involving repeated feeding with much larger (50-to 100-fold) doses of free MBP. Different from the latter treatment, which led to decreased production of interferon-y in lymph nodes, lowdose oral CTB-MBP treatment was associated with increased interferon-y production. Most importantly, low-dose oral CTB-MBP treatment greatly reduced the level of leukocyte infiltration into spinal cord tissue compared with treatment with repeated feeding of large doses of MBP. These results suggest that the protection from experimental autoimmune encephalomyelitis achieved by feeding CTB-conjugated myelin autoantigen involves immunomodulating mechanisms that are distinct from those implicated by conventional protocols of oral tolerance induction.
Experimental allergic encephalomyelitis (EAE) is a CD4+ T-cell-dependent paralytic autoimmune disease of the central nervous system (CNS) that can be induced in experimental animals by the injection of myelin-derived autoantigens and peptides (1) . This experimental disease serves as a widely studied model for human autoimmune inflammatory demyelinating disorders such as multiple sclerosis (2) .
Oral administration of antigens including autoantigens has long been recognized as a method to prevent peripheral T-cell responses and, in the case of autoantigens, has also been shown to prevent or delay the onset of several experimental autoimmune diseases (3) (4) (5) (6) (7) (8) (9) , including EAE (5, 6) . Major problems recognized with strategy is that it requires feeding large if not massive doses of autoantigens and it is generally less efficient in an immune as opposed to a naive host (10, 11) . The latter problem has limited the therapeutic potential of this strategy.
We have recently shown (12) that oral administration of minute amounts of prototype particulate and soluble protein antigens conjugated to cholera toxin B subunit (CTB), the nontoxic receptor-binding moiety of cholera toxin, can readily induce tolerance in the peripheral T-cell compartment and is effective not only in naive but also in systemically sensitized animals. We now report that oral administration of minute amounts of an autoantigen, myelin basic protein (MBP), coupled to CTB can prevent EAE in Lewis rats, a particularly susceptible strain. Most importantly, the oral CTB-MBP is also effective when given after induction of the experimental EAE disease and reduces leukocyte infiltration into the CNS.
MATERIALS AND METHODS
Animals and Induction of EAE. Female Lewis rats (7 to 8 weeks old) were purchased from Harlan (Blackthorn, United Kingdom). To induce EAE, animals were injected in the hind footpads with 50 j,g of guinea pig MBP (prepared as described below) emulsified in Freund's complete adjuvant (CFA) containing killed Mycobacterium tuberculosis H37Ra cells (Difco; 5 mg/ml).
Animals were examined daily for clinical signs of EAE. Clinical severity was scored as follows: 0, no disease; 1, limp tail; 2, tail paralysis and hind limb weakness; 3, hind limb paralysis; 4, tetraplegia; 5, death.
Antigens and Preparation of CTB-Antigen Conjugates. Highly purified CTB, free of any contaminating A subunit, was produced in a mutant strain of Vibrio cholerae deleted of the cholera toxin A subunit gene and transfected with a plasmid encoding CTB (13, 14) . CTB was purifed from the bacterial culture supernatants by sequential precipitation and gel filtration chromatography (14) . MBP was purified from guinea pig spinal cord and brain tissue by the method of Deibler et al. (15 2-mercaptoethanol, and antibiotics. MBP (10 ,g/ml), M. tuberculosis purified protein derivative (10 ,ug/ml) (Serum Institute, Copenhaguen, Denmark), or Con A (2 ,ug/ml) was added at the start of the culture period and aliquots of supernatants were collected at 24 hr for interleukin 2 (IL-2) measurement (see below). Proliferation was assessed by measurement of [3H]thymidine uptake during the last 16 hr of a 72-hr culture period. Results were expressed as mean stimulation indices, calculated as the ratio of radioactivity incorporated in antigen-or mitogen-exposed cultures compared with replicate cultures exposed to medium alone.
Cytokine Assays. Culture supernatants from lymph-node MNCs were assayed for IL-2 contents by using the murine IL-2-dependent CTLL-2 subclone (18). IL-2 levels were determined by measuring [3H]thymidine uptake by CTLL cells exposed to test supernatants,' and values were calculated in units per ml by reference to a standard curve obtained by assaying known amounts of recombinant human IL-2 (Genzyme).
Interferon-y (IFN-,y) production was determined by reverse ELISPOT assay (19) using mouse monoclonal anti-rat IFN-,y antibody (DB-1 clone, provided by Peter van der Meide, Biomedical Primate Research Centre, Rijswijk, The Netherlands) immobilized on nitrocellulose membranes (Millipore) as solid-phase capture system and rabbit antiserum to rat IFN-,y as primary detection reagent. Briefly, popliteal and mesenteric lymph node cells were incubated for 48 hr in anti-IFN-,y-coated wells with MBP (10 ,g/ml). Plates were then thoroughly washed with PBS/0.05% Tween 20, and individual wells were exposed to primary anti-IFN-,y antiserum appropriately diluted in wash buffer. After sequential incubation with biotinylated swine anti-rabbit Ig (Dakopatts), avidinperoxidase (Sigma), and chromogen substrate, plates were thoroughly washed with running water and examined for the presence (Table 3 ). In contrast, animals fed a small dose (50 ,g) of unconjugated MBP on three consecutive occasions after disease induction had normal proliferative responses to MBP. Irrespective of treatment, lymph-node MNCs from all animals injected with MBP in CFA mounted proliferative responses to Con A and purified protein derivative that were comparable to those of saline-fed control animals ( Table 3) .
IL-2 levels in MBP-stimulated lymph-node MNC cultures from rats treated with low-dose oral CTB-MBP conjugate or repeated high dose of unconjugated MBP were markedly reduced compared with those from saline-fed control animals or from animals given a low dose of MBP admixed with free CTB (Fig. 1) . Lymph-node MNC cultures from rats fed repeated large doses of unconjugated MBP had decreased numbers of IFN-y-secreting cells compared with saline-fed control animals or animals given a low dose of MBP admixed with free CTB (Fig. 1) . Unexpectedly, the frequency of IFN-y-secreting cells in cultures of MBP-stimulated lymph node cells was markedly increased in animals treated with low-dose CTB-MBP (Fig. 1) . Thus, oral treatment with lowdose CTB-MBP appears to involve a modification of the peripheral Th-1 cytokine response to MBP, which is distinct from that observed after treatment with large doses of free
MBP.
Decreased DTH Reactivity to MBP in Rats Treated with Oral CTB-MBP Conjugate. Skin DTH reactivity in rats treated with a low-dose oral CTB-MBP conjugate or repeated large doses of unconjugated MBP given after EAE induction was determined after ear challenge with MBP. As shown in Fig. 2 , animals treated with 50 jig of MBP conjugated to CTB and given orally on one or three occasions after EAE induction had markedly reduced DTH reactivity to MBP compared with animals fed comparable or even much larger (five 1-mg doses) Reciprocal effects of oral CTB-MBP treatment on IL-2 and IFN--y production by lymph node cells from Lewis rats. Animals were immunized with MBP in CFA on day 0 and fed with CTB-MBP conjugate, a mixture of unconjugated MBP and free CTB, or five consecutive high doses of unconjugated MBP. On day 15, popliteal lymph node cells were harvested and cell-free IL-2 levels and numbers of IFN-y-producing cells were determined after 24 hr and 48 hr, respectively. IL-2 levels and mean numbers of IFN-y-secreting cells were determined on six animals per experimental group and are expressed as the mean ± SD. Significant differences (Wilcoxon rank test) with saline-fed animals are indicated (*, P < 0.05; **, P < 0.01).
amounts of MBP, although the later animals had a significantly reduced ear skin DTH reactivity to MBP compared with saline-fed control animals.
Rats Protected from EAE by Oral CTB-MBP Treatment Have Fewer Infiltrating Leukocytes in Their Spinal Cords. Histological examination of spinal cord specimens from rats injected with MBP in CFA and subsequently treated with oral CTB-MBP showed a very marked reduction in the magnitude of leukocyte infiltration. Few if any MNC infiltrate could be seen in these animals (Fig. 3) . Occasional minor perivascular infiltrates were observed in spinal cord tissue specimens from CTB-MBP fed animals, and in most instances the white matter . -H . g i t . -, > . j * . . . . . . , -. . . . . . . . 4 . . . . . . . . . . s -- was judged free of inflammatory cells. In contrast, numerous perivascular infiltrates and diffuse accumulations of MNCs in the spinal cord white matter were observed in specimens examined from saline-fed animals (Fig. 3) . Furthermore, in animals fed repeated large doses of free MBP, spinal cord specimens displayed focal collections of MNCs located around blood vessels and clusters of inflammatory cells in the white matter, although the density of infiltrating cells was relatively lower in animals fed large doses of MBP compared with saline-fed control rats (Fig. 3) (3) (4) (5) (6) (7) (8) (9) . In most instances, the doses of antigens employed have been 100-800 times higher than the doses of MBP now found to be effective when coupled to CTB, and in general the tolerizing effects have been partial (5, 6) . Depending on the dose of antigen fed, oral tolerance appears to involve different mechanisms. Thus, oral administration of very large (20 mg) doses of MBP administered repeatedly have been shown to prevent EAE by either direct deletion of autoreactive cells (20) or anergy of MBP-reactive Thl cells producing IL-2 and IFN-,y (21, 22) . On the other hand, Weiner et al. (23, 24) have shown that relatively lower yet copious doses (several of milligrams) of MBP administered repeatedly can also protect animals from EAE and have proposed a mechanism involving the recruitment from the gut into the CNS of Th-2-like regulatory cells capable of producing cytokines (transforming growth factor ,B, IL-4, and/or IL-10) known to antagonize Th-1-driven cell-mediated immune responses (25) . Since we did not attempt to measure Th-2 cytokines (e.g., IL-4 or IL-10), the reduced levels of IL-2 and IFN-,y observed in cultures of MBP-stimulated lymph node cells from animals fed large doses of myelin autoantigen could still be compatible with either of the above scenarios.
However, a quite unexpected finding in this study was that, in contrast to proliferative responses and IL-2 production, which were suppressed to a similar extent after repeated feeding with large doses (five 1-mg doses) of free MBP or with even a single dose of 50 jig of CTB-conjugated MBP, IFN-,y production was not suppressed in CTB-MBP-fed animals, at variance with animals fed unconjugated MBP. In fact, there was instead a significant increase in IFN-,y production in cultures of MBP-stimulated lymph node cells from CTB-MBP-fed animals compared with nonfed animals. Since IFN--y is believed to play an essential role in the recruitment of lymphocytes at sites of inflammation (26) , this observation is relatively intriguing. However, it has recently been described (27) that parenterally induced immunological tolerance with model antigens is associated with decreased IL-2 production and elevated IFN--y (and IL-4) production in draining lymph nodes, a finding similar to the one we observed when feeding CTB-MBP conjugate. Although in vitro-induced IFN-,y production may not reflect the situation at sites of potential tissue injury, it is worth recalling (i) the protective effects of IFN-,y administration in EAE (28) and the diseaseenhancing effects of anti-IFN-y antibody treatment (29, 30) , (ii) the known antiproliferative properties of IFN-,y (31, 32) , (iii) the observation that IFN-,y can promote the release of active transforming growth factor ,B (33), a cytokine known to protect animals against EAE (34, 35) , and (iv) recent findings indicating that in vitro neutralization of IFN--y restores and even increases autoantigen-induced proliferation of lymph node cells from animals orally tolerized with CTB-MBP (unpublished data). We have also shown that in humans oral administration of CTB-containing vaccines leads to increased IFN-,y production in the gut (36) and to the generation of circulating T cells capable of producing IFN-,y but not IL-2 when challenged ex vivo with fed antigen (37) . It thus appears that the cytokine pattern associated with protection against clinical EAE after feeding MBP alone or conjugated to CTB differs. These observations not only suggest that at least partly distinct mechanisms govern the protective effects of these different treatment regimens but also support the notion that IFN-,y acts as an antiinflammatory mediator in EAE.
Another surprising finding was the almost lack of infiltrating leukocytes in the spinal cord of CTB-MBP fed rats. If we assume that mucosally derived regulatory cells with an unusual cytokine repertoire, unlike Th-1 cells and Th-2 cells, do not migrate into the CNS, they may still leave the gut via draining (mesenteric) lymph nodes and enter the circulation and peripheral lymphoid organs where they would interfere with the recruitement and migration of inflammatory leukocytes from the peripheral lymphoid compartment to the CNS. The finding that large numbers of IFN-y-producing cells appear in lymph nodes from animals treated with oral CTB-MBP is compatible with such a mechanism. Further studies on the expression of adhesion molecules on these various T-cell subsets could be valuable.
We conclude that oral treatment with small doses of MBPconjugated to CTB can protect rats from EAE and induces a modification in the cytokine repertoire of encephalitogenic T cells and renders these cells unable to infiltrate the CNS. Given these encouraging results, we are currently evaluating this approach in chronic models of autoimmune demyelinating disorders. We have also documented the efficiency of this strategy of tolerance induction in animal models of spontaneous autoimmune diabetes and in experimentally induced autoimmune arthritis (unpublished results). These promising findings in animals warrant further studies on the efficiency of this strategy in humans.
